Predix Pharmaceuticals to be acquired

Predix President and CEO Dr. Michael G. Kauffman will become the CEO of the combined company.

By DAVID YANKELEWITZ
April 5, 2006 08:15

Ramat Gan-based Predix Pharmaceuticals Holdings, Inc. has agreed to be acquired by US-based EPIX Pharmaceuticals Inc. for $90 million, including the assumption of net debt at closing. EPIX will pay shareholders of privately held Predix approximately $35 million in cash, stock, or a combination of both, depending on the achievement of certain clinical and strategic milestones, as well as 47% of the combined company's shares outstanding. Predix President and CEO Dr. Michael G. Kauffman will become the CEO of the combined company.


Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS

Israel Weather
  • 16 - 27
    Beer Sheva
    18 - 23
    Tel Aviv - Yafo
  • 16 - 23
    Jerusalem
    16 - 22
    Haifa
  • 23 - 36
    Elat
    17 - 28
    Tiberias